Zacks Investment Research downgraded shares of HORIZON PHARMA (HZNP) from OUTPERFORM to NEUTRAL on February 05, 2014, with a target price of $10.60.
Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company's products include HZT-501 for the treatment of pain, osteoarthritis, and rheumatoid arthritis LODOTRA for rheumatoid arthritis and asthma TRUNOC for pain-related diseases and HZN-602 for the treatment of pain and arthritis. Horizon Pharma, Inc. is headquartered in Northbrook, Illinois.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on HORIZON PHARMA (HZNP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment